Mutations and dysregulation of KMTs are commonly observed in cancer. For example, the overexpression of EZH2, a KMT that catalyzes H3K27me3, is frequently detected in aggressive forms of cancer and is associated with poor prognosis. Such dysregulation can lead to the inappropriate silencing of tumor suppressor genes or activation of oncogenes, contributing to the development and progression of cancer. Therefore, KMTs are considered potential targets for therapeutic intervention in oncology.
